Security Snapshot

Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD) Institutional Ownership

CUSIP: 140755307

13F Institutional Holders and Ownership History from Q2 2025 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

56

Shares (Excl. Options)

2.23MFull value: 2,226,613 · shares · 30 Jun 2026

Price

$1.90

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock, par value $0.001 per share
Symbol
TVRD on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
2,226,613
Latest holder snapshot 5 signals
Total 13F value
$4,243,111
Portfolio coverage rank
0%
Share change
-473,677
Value change
-$1,131,830
Number of holders
56
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
9,470,889
SEC-reported price per share
$1.25
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 140755307.
  • 56 institutions reported positions in Q2 2026.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 66 to 56 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $8.6MFull value: $8,596,315 · USD · 31 Mar 2026
    to
    $4.24MFull value: $4,243,111 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 56 institutions filings for Q2 2026.

Open SEC evidence

Security key

140755307

13F reference period

Q2 2026

13F holders

56

13D/G owners

3

CIK / CUSIP context first

Open Q2 2026 holders TVRD full holder history Tvardi Therapeutics, Inc. SEC filings Tvardi Therapeutics, Inc. company facts Tvardi Therapeutics, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
3
Security
TVRD
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Slate Path Capital LP 7.5% $19,257,627 704,118 Slate Path Capital LP 30 Jun 2025
DePinho Ronald A 4.5% $1,939,164 426,190 Ronald A. DePinho 31 Dec 2025
Vifor (International) Ltd 2.2% $4,725,695 205,465 Vifor (International) Ltd. 15 Apr 2025
As of 30 Jun 2026, 56 institutional investors reported holding
2.23MFull value: 2,226,613 · shares · 30 Jun 2026
shares of Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD). This represents 24% of the company’s total
9.47MFull value: 9,470,889 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
23%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Slate Path Capital LP 7.4% 704,118 0% 0.02% $1,337,824
VANGUARD CAPITAL MANAGEMENT LLC 3.6% 344,382 -0.09% 0% $654,326
AMERICAN FINANCIAL GROUP INC 2.4% 223,659 0% 0.15% $424,952
UBS Group AG 1.2% 111,133 +120% 0% $211,153
SILVERCREST ASSET MANAGEMENT GROUP LLC 1.1% 101,034 0% 0% $191,965
BlackRock, Inc. 1% 95,478 -75% 0% $181,408
RENAISSANCE TECHNOLOGIES LLC 0.97% 91,409 -0.75% 0% $173,677
GEODE CAPITAL MANAGEMENT, LLC 0.95% 90,350 -50% 0% $171,741
MORGAN STANLEY 0.82% 77,845 +6.8% 0% $147,905
Duncan Williams Asset Management, LLC 0.67% 63,241 0% 0.03% $120,158
VANGUARD FIDUCIARY TRUST CO 0.47% 44,710 -4.6% 0% $84,949
Russell Investments Group, Ltd. 0.46% 43,228 +85% 0% $82,133
STATE STREET CORP 0.36% 33,900 -65% 0% $64,410
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.35% 33,165 0% $63,014
AQR CAPITAL MANAGEMENT LLC 0.29% 27,096 -36% 0% $51,483
NORTHERN TRUST CORP 0.23% 21,836 -56% 0% $41,489
Savant Capital, LLC 0.21% 19,462 0% $49,434
GSA CAPITAL PARTNERS LLP 0.19% 17,885 0% $34,000
DIADEMA PARTNERS LP 0.18% 16,607 0.01% $31,553
XTX Topco Ltd 0.16% 14,868 0% $28,249
BROWN ADVISORY INC 0.12% 11,200 0% $21,280
Arax Advisory Partners 0.12% 11,003 +32% 0% $20,906
Qube Research & Technologies Ltd 0.11% 10,210 0% $19,399
Persistent Asset Partners Ltd 0.04% 4,253 0% $8,081
PNC Financial Services Group, Inc. 0.04% 3,518 +578% 0% $6,685

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
6
Headline period
Q2 2026
Rows shown
1-6 of 6
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 25,226 $31,533 -$18,201 $1.25 8
2026 Q2 2,226,613 $4,243,111 -$1,131,830 $1.90 56
2026 Q1 2,703,203 $8,596,315 -$546,130 $3.18 66
2025 Q4 2,824,911 $12,111,919 -$18,315,547 $4.30 64
2025 Q3 2,603,814 $101,367,779 +$26,943,937 $38.97 64
2025 Q2 1,922,982 $44,387,703 +$44,380,704 $23.33 48
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .